MARKET

EARS

EARS

Auris Medical Holding Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.9050
+0.0050
+0.56%
Opening 14:06 07/09 EDT
OPEN
0.8943
PREV CLOSE
0.9000
HIGH
0.9080
LOW
0.8750
VOLUME
49.23K
TURNOVER
--
52 WEEK HIGH
3.200
52 WEEK LOW
0.6500
MARKET CAP
4.17M
P/E (TTM)
-0.3842
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average EARS stock price target is 14.59 with a high estimate of 14.59 and a low estimate of 14.59.

EPS

EARS News

More
61 Stocks Moving In Tuesday's Mid-Day Session
Gainers Mmtec, Inc. (NASDAQ: MTC) shares jumped 98.2% to $2.18 in pre-market trading after reporting its financial results for the year ended December 31, 2019. Revenues jumped 647% to $200,797, in 2019.
Benzinga · 05/26 16:29
Auris Medical Announces Positive Top-Line Data from AM-201 Phase 1b Study in Antipsychotic-Induced Weight Gain and Provides Update on TRAVERS Phase 2 Study
GlobeNewswire · 05/26 13:30
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB) gained about 6% for the week.
Benzinga · 05/10 19:40
Here's Why We Worry About Auris Medical Holding's (NASDAQ:EARS) Cash Burn Situation
Simply Wall St. · 05/10 15:39
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck & Co., Inc. (NYSE: MRK) and Pfizer Inc.
Benzinga · 05/03 12:46
Auris Medical reports FY results
seekingalpha · 04/16 16:04
Auris Medical Provides Business Update and Reports Second Half and Full Year 2019 Financial Results
GlobeNewswire · 04/16 12:00
Auris Medical FY19 Total Opex CHF 7.3M vs CHF11M In FY18, EPS CHF(2.28) vs CHF(14.46) In FY18
Benzinga · 04/16 11:04

Industry

Biotechnology & Medical Research
-0.35%
Pharmaceuticals & Medical Research
-0.72%

Hot Stocks

Symbol
Price
%Change

About EARS

Auris Medical Holding AG is a Switzerland-based biotechnology company engaged in developing pharmaceutical products for the treatment of inner ear disorders and mental health supportive care. The Company focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The Company operates through subsidiaries in Switzerland, Ireland and the United States.
More

Webull offers kinds of Auris Medical Holding Ltd stock information, including NASDAQ:EARS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EARS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EARS stock methods without spending real money on the virtual paper trading platform.